Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.

Abstract

Urate lowering therapy in this country has mainly been achieved by the use of allopurinol and probenecid. A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout. In this report, we describe the management of a patient with chronic tophaceous gout using febuxostat. The reduction in serum uric acid… (More)

Topics

2 Figures and Tables

Cite this paper

@article{Hilmi2012UseON, title={Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.}, author={B A Hilmi and M I Asmahan and Azmillah Rosman}, journal={The Medical journal of Malaysia}, year={2012}, volume={67 1}, pages={125-6} }